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ABSTRACT 
The aim of this thesis is to investigate the roles of caspase-8 and caspase-3 in microglia and 
in brain disorders, beyond their function in apoptosis. 
Microglia are resident immune cells of the central nervous system and act as the first line of 
defense against invading pathogens and other types of brain insults. They are important for 
normal brain homeostasis and can get rapidly activated upon infection or damage in the brain. 
However, dysregulated and overactivated microglia have also been reported to cause 
neurotoxicity and can further contribute to the damage in neurodegenerative diseases. 
Caspases are a family of proteases that are important for signaling pathways controlling cell 
death, inflammation, proliferation and differentiation. Caspase-8 and -3 are well known for 
their functions in apoptosis, but can also be involved in other processes. We have earlier 
shown that upon pro-inflammatory stimuli, microglia activate caspase-8 and -3/7 which 
regulate their activation through a PKCδ-dependent pathway, without triggering of cell death. 
In the first paper we investigate why caspase-3 under some circumstances kills the cells, but 
under others, like activation of microglia, does not.  We show that upon pro-inflammatory 
stimuli of microglia, cIAP2 regulates the processing of caspase-3 so that it remains in the 
cytoplasm. Under cell death conditions caspase-3 can be fully processed and thereby enter the 
nucleus and exert its apoptotic functions. 
In order to provide genetic evidence of caspase control of microglia activation, we have 
created a model in which caspase-8 is conditionally knocked out in microglia. The CASP8 
knock-out mice showed a reduction in pro-inflammatory activated microglia, which were 
associated with reduced neurotoxicity in a mouse model of Parkinson´s disease. We are also 
presenting data on the temporal and spatial activation of caspase-8 and -3 in microglia cells in 
human subjects who suffered a stroke. In the last paper we screened for genes involved in the 
metabolism of amyloid precursor protein in patients with late-onset Alzheimer´s disease. 
Significant association was found for rare variants of CASP8 and late-onset of the disease. 
For two of the variants we performed functional studies, which indicated an altered caspase-8 
protein expression and reduced enzymatic activity. 
In summary, we have provided genetic evidence for caspase regulation of microglia pro-
inflammatory activation and described a mechanism for how caspases prevent killing of cells 
during activation. We also describe the expression pattern of caspases in microglia cells after 
stroke, and provide evidence of rare mutations in caspase-8 associated with late-onset 
Alzheimer´s disease. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Mikroglia är hjärnans egna immunceller. De är viktiga för att försvara hjärnan mot 
infektioner och hjälpa till att läka den vid skador. Men vid vissa sjukdomar kan de även bli 
överaktiva och skada nervcellerna, därför är det viktigt att förstå hur de aktiveras och hur de 
kan regleras. 
Kaspaser är en familj av enzymer som reglerar många viktiga processer i cellerna. Kaspas-8 
och -3 är vanligtvis aktiva i celldödsprocessen, men vi har i en tidigare studie upptäckt att de 
även är involverade i aktiveringsprocessen av mikroglia. Men hur kan det komma sig att 
aktiveringen av samma kaspaser kan leda både till celldöd och till aktivering? Vi har hittat 
mekanismen för hur det fungerar, vilket är beskrivet in en av artiklarna i denna avhandling.  
Vi har även undersökt vad som händer om vi tar bort genen för kaspas-8 enbart i 
mikrogliacellerna i en musmodell. Det ledde till att mikroglia var svårare att aktivera, vilket 
betyder att kaspas-8 är viktig för aktiveringsprocessen. I en musmodell av Parkinsons 
sjukdom så såg vi intressant nog att reglerad aktivering av mikroglia även ledde till att färre 
nervceller dog. I en annan studie har vi visat att kaspas-8 och -3 uttrycks i aktiverade 
mikrogliaceller efter en stroke. Vi har undersökt vävnad från strokepatienter och kartlagt var 
och när kaspaserna blir aktiverade. I den sista studien screenade vi en stor grupp patienter 
med sporadisk Alzheimers sjukdom för att leta efter nya genmutationer. Intressant nog hittade 
vi två nya ovanliga mutationer i kaspas-8 genen som vi kunde koppla till patienter som 
utvecklat Alzheimers. Vi kunde även visa att dessa mutationer i kaspas-8 leder till försämrad 
enzymatisk aktivitet för kaspas-8. 
Sammanfattningsvis så har vi här visat hur kaspas-8 och -3 är reglerade och involverade i 
aktiveringsprocessen av mikroglia samt i hjärnsjukdomar. Denna kunskap är viktig för att 
bättre kunna förstå hur mikrogliaceller och kaspaser fungerar, samt öka kunskapen om 
hjärnans sjukdomar. 
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1 INTRODUCTION 
1.1 MICROGLIA 
1.1.1 The brain 
The brain is a part of the central nervous system (CNS) and consists of several cell types, 
which are often roughly divided into neuronal and glial cells. Neuronal cells are arranged in 
networks (circuits) and communicate with each other via rapid electrochemical signals. The 
glial cells consist of oligodendrocytes, astrocytes and microglia. The oligodendrocytes form 
and maintain the myelin sheets that insulate the neuronal axons and improve signal speed. 
The astrocytes are involved in maintaining the blood-brain barrier (BBB) integrity and the 
extracellular ion balance, the buffering of neurotransmitters and providing neuronal metabolic 
support 
1
. Microglia are the resident innate immune cells of the brain. They act as the first 
line of defense against pathogens and contribute to brain homeostasis 
2
. The brain is partially 
separated from the body and the circulating blood flow by the BBB. This diffusion barrier is 
formed by endothelial cells and pericytes, and hinders influx of most compounds to enter the 
brain. During inflammation the BBB becomes more permeable, and may allow larger 
compounds and other immune cells to enter the brain 
3
. 
1.1.2 Microglia 
Microglia can be distinguished from the other glial cells by their origin, morphology, 
functions in the brain and gene expression patterns 
2,
 
4
. Microglia cells are constantly 
scanning the brain for potential threats, and are rapidly responding to infections or injury. 
They then undergo a multistage activation process and can acquire different phenotypes. The 
activated microglia cells have the potential to migrate to the site of infection or injury, 
undergo proliferation and release pro- or anti-inflammatory compounds and phagocytose 
cells or debris 
2, 4
. 
Microglia cells were first described by Río-Hortega in 1919 
5
. He gave them their name and 
classified them as “the macrophages of the brain”. He also described the different 
morphological appearances the cell can achieve in scavenging, or “resting”, state and upon 
activation, illustrated by many tissue stainings and drawings. It was also described how the 
cells were distributed in the brain, and their ability to migrate, proliferate and phagocytose  
5,6
. 
1.1.3 Origin and distribution 
The developmental origin of microglia has been a matter of debate for quite some time. Due 
to the similarities to peripheral monocytes and macrophages, microglia cells were first 
suggested to be of hematopoietic origin. Although monocytes are able to enter the brain and 
assume microglia/macrophage morphology, this only occurs under specific conditions when 
the BBB is impaired. It has now been shown that microglia originate from the embryonic 
yolk sac during development 
7
. They are derived from erythromyeloid progenitor cells that 
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resemble macrophages and enter the brain via the circulatory system to colonize the brain. 
Microglia then go through a developmental program where they proliferate and assume the 
typical microglia ramified morphology and spread throughout the brain 
4
.  
The number of microglia cells varies depending on the region of the brain. Microglia are 
reported to represent 5-12 % of all glial cells in the normal mouse brain, with regional density 
differences 
8
. In the normal human brain, microglia represent 0.5 -16.6 % of all brain cells, 
with substantially higher number of microglia in the white than the grey matter 
9
. The 
population of microglia remains relatively stable through life, and is maintained by self-
renewal 
10
. 
Depending on their location in the brain and the surrounding microenvironment, microglia 
can differ in morphology with great variation in body size and length and branching of 
processes even in the normal brain. Microglia are then generally described having a small 
body and being highly ramified. However, the morphology can alter from more compact and 
rounded state with short processes at sites lacking the BBB, to microglia cells with long 
processes following the longitudinal axis of nerve fibers in the white matter, to the radially 
branched microglia that can be found throughout the grey matter 
8
. 
1.1.4 Microglia and brain homeostasis 
Although the state of microglia in the healthy brain is sometimes referred to as “resting”, 
there seems to be no periods of inactivity since microglia processes are highly dynamic and 
constantly in motion to inspect their microenvironment 
11, 12
. The term scavenging or 
surveying seems to fit the state of microglia in the normal brain better. Besides their role as 
immune cells, they also contribute to the brain homeostasis. Microglia constantly interact 
with neurons in the developing brain as well as in the adult brain. If these interactions are 
disturbed, it can have severe consequences on the brain development and function 
4
. 
In the postnatal development many new synapse connections are formed, but only some are 
maintained and others have to be eliminated. Microglia participate in the synaptic remodeling 
by survey the synaptic maturation and actively engulfing synaptic material 
13, 14
. During 
development and adulthood, microglia also contributes to the formation of neuronal circuits 
and promote neuronal survival by releasing trophic factors, e.g. insulin-like growthfactor-1 
(IGF-1), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), nerve 
growth factor (NGF), and brain-derived neurotrophic factor (BDNF) 
15, 16, 17
. 
Microglia also play a role in neuronal cell death. During development, many immature 
neurons undergo programmed cell death as part of the developmental program. This can be 
induced by neuronal intrinsic factors as well as factors released from microglia, for example 
NGF and reactive oxygen species (ROS) 
18, 19
. Microglia are also important for the removal of 
the dead cells throughout life. Phagocytosis of neuronal cells during development as well as 
removal of dead cells in the adult brain is vital to maintain homeostasis. Without the removal 
of dead cells and debris, the brain deteriorates and can result in neurological dysfunction 
4
. 
Microglia can participate in the cleanup through phagocytosis, without initiating an 
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inflammatory response. Non-inflammatory phagocytosis can be mediated via triggering 
receptor expressed on myeloid cells-2 (TREM2) 
4
. Microglia can detect dying cells by their 
expression of “find me” signals, such as fractalkine (CX3CL1) or lysophosphatidylcholine 
(LPC), and “eat me” signals, such as phosphatidylserine (PtdSer) or annexin I, which induce 
the microglial phagocytosis of the cells 
20
.  
1.1.5 Activation 
Microglia cells are very plastic and can respond to a large variety of challenges. These cells 
are equipped with many receptors that can detect a wide range of molecules associated with 
infection, injury or neurodegeneration. They then undergo a rapid change in gene expression, 
functional behavior and morphological transformations 
2, 4
. This is called microglia 
activation, although one might argue that this is just a shift in activation state, going from 
maintenance and surveillance to an immunologically active cell. 
The scavenging microglia have a ramified morphology with a small cell body and thin, 
branched processes. Upon activation, microglia undergo a transformation to different 
functional states, depending on the cause of activation. Microglia can acquire bushy, rod 
shaped or various stages of rounded morphologies, with the characteristic macrophage-like 
amoeboid form with retracted protrusions and enlarged cell body 
21, 22, 23.
 They become motile 
and can actively move to the site of injury or infection by following a chemotactic gradient or 
proliferate at the site upon activation. Microglia activation includes upregulation and 
rearrangements of surface receptors needed for interactions with surrounding cells and 
extracellular matrix, changes in intracellular enzymes and release of various inflammatory 
and immunoregulatory compounds. Microglia can phagocytose damaged cells, tissue debris 
or microbes, as well as release chemoattractive factors in order to recruit immune cells from 
the circulation to help fighting infections 
2, 4
. 
Microglia cells are equipped with innate pattern-recognition receptors (PRRs) that recognize 
foreign antigens, which allow them to respond to many types of infectious agents, including 
bacteria, fungi, parasites and viruses. The PPRs include toll-like receptors (TLRs), RIG-I-like 
receptors (RLRs), NOD-like receptors (NLRs) and C-type lectin receptors which recognize 
conserved structural motifs of pathogen-associated molecular patterns (PAMPs) 
24
. For 
example, microglia detect bacterial infections through e.g. TLR2, TLR3, TLR4 and TLR9, 
which recognize the bacterial lipopeptides, polyinosinic-polycytidylic acid, 
lipopolysaccharides (LPS) and bacterial CpG DNA respectively 
25
. Upon activation, 
microglia can become phagocytes and secrete many proinflammatory cytokines, including 
TNF, IL-1β, IL-6 and inducible nitric oxide synthase (iNOS), reactive nitrogen (RNS) and 
oxygen species (ROS) to kill the bacteria 
26, 27, 28
. They also release chemoattractants, such as 
monocyte chemoattractant protein1 (MCP-1) and macrophage inflammatory protein-2 (MIP-
2) to recruit immune cells from the periphery to clear the infection 
29,
 
30
. Viral agents are also 
recognized by the PPRs. They induce an acute inflammatory response with release of many 
proinflammatory cytokines (IFN-β, IFN-γ, TNF, IL-1β, IL-6, IL-12), chemoattractants as 
well as activation of microglial antigen-presenting functions. Microglia are able to upregulate 
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co-stimulatory molecules like CD40 and CD86, and major histocompatibility complex I and 
II (MHC-I/II). They also have the ability for antigen presentation to infiltrating adaptive 
immune cells, but do not seem to be as efficient as professional antigen presenting cells 
(APCs) 
4,
 
31,
 
32
. 
In addition to the PRRs, microglia also express many other types of receptors that contribute 
to the recognition of damage associated molecular patterns (DAMPs) released in high 
amounts from damaged or dying cells. For example, detection of the DAMP signal adenosine 
triphosphate (ATP) by purinergic receptors or high-mobility group box 1 (HMGB1) by 
TLR2, TLR4 and receptor for advanced glycation end-products (RAGE) rapidly activates 
microglia 
33,
 
34
. In conditions like traumatic brain injury or ischemic damage, large amounts 
of DAMPs are released from dying cells and attract microglia to the site of the injury 
12
. They 
trigger an acute inflammatory reaction with release of inflammatory mediators and 
phagocytosis. However, if the inflammation is sustained and reaches a chronic phase, this can 
lead to deleterious effects on the neuronal population. If the inflammation is not resolved 
after clearance of the damaged area, the chronically activated microglia continue to release 
cytotoxic compounds and induce oxidative stress. This cause more neuronal loss, and have 
been detected in several neurodegenerative diseases 
35,
 
36
. Microglia have also been shown to 
induce neuronal death by phagoptosis. Under inflammatory conditions, microglial release of 
soluble mediators, such as peroxynitrile or TNF, can induce neuronal phosphatidylserine 
exposure and lead to microglial phagocytosis of the stressed-but-viable neurons 
37, 38
. 
1.1.6 Phenotype classification 
The generalized classification system for describing macrophages is also commonly used for 
microglia. Although simplified, it can be a useful tool to describe the type of activation the 
cells are undergoing. Under physiological conditions, microglia are in scavenging state, 
surveying the local microenvironment. Disturbance in brain homeostasis can induce 
microglia activation, for which the activation stages are typically described as classical 
activation (M1) and alternative activation (M2) 
22
. 
The classical activation is a defensive state and a typical response to an infectious agent. 
Microglial activation by e.g. IFNγ, LPS or other TLR activators are common, and results in 
release of high amounts of pro-inflammatory cytokines (e.g. TNF, IL-1β, IL-18) and 
oxidative metabolites (ROS, NO), enhanced microbicidal capacity and expression of co-
stimulatory molecules 
22,
 
39,
 
40
. 
The alternative activation is more of a reparative, matrix remodeling and anti-inflammatory 
response. It is characterized by release of anti-inflammatory cytokines (e.g. IL-10) and matrix 
metalloproteases (e.g. MMP1 and -12) upon e.g. IL-4 or IL-13 recognition. This category has 
been further divided into functions, related to tissue repair and wound healing, as well as a 
state of acquired deactivation 
22,
 
39,
 
40
. 
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Lately it has been discussed that it is more likely that there is a whole spectrum of activation 
states, and the cell can shift between activation states either based on the type of stimulus or 
the previous activation state (Figure 1) 
40,
 
41
. 
 
 
 
Figure 1. Microglia have a broad spectrum of activation states that they can shift between. 
 
1.1.7 Microglia markers 
As for today, there is not one single marker that is ideal for detecting microglia in tissue. In 
the intact CNS, it is possible to distinguish microglia from the surrounding cells by e.g. the 
widely used Ionized calcium-binding adapter molecule–1 (Iba1) that mark all microglia, with 
an increased expression upon activation 
42,
 
43
. Other general markers used for microglia are 
Cd11b/MAC1/OX42, F4/80, IB4 and tomatolectin. A frequently used marker for activated 
microglia with lysosomal activity is CD68. There are also several markers that can be used 
for subsets of activated microglia, like MHCII, complement receptors or scavenger receptors  
2,
 
22,
 
39
. In pathologic conditions with breakdown of the BBB, blood derived macrophages can 
enter the brain. They express very similar spectrum of receptors as microglia, and it is 
problematic to distinguish between the two cell types. In experimental studies, double-
transgenic mice with CX3CR1-GFP labeled microglia and CCR2-RFP labeled macrophages 
can be used. Here it is possible to distinguish the two cell types, even under pathological 
conditions when macrophages have entered the brain and work together with microglia 
44,
 
45
.  
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1.2 NEURODEGENERATIVE DISORDERS 
1.2.1 Microglia in disease 
Microglia activation is important for host defense and to resolve diseases of the brain. 
However, dysregulated and overactivated microglia can induce detrimental neurotoxic effects 
by production of cytotoxic factors which contribute to neuronal cell death 
36
. In several 
neurodegerative disorders, high numbers of microglia are detected. For example in 
Alzheimer’s disease (AD) and Parkinson’s disease (PD), protein aggregates and dying 
neurons can activate microglia and result in chronic inflammation and neuronal loss 
46
. 
Microglia have also been linked to pathology and disease progression in other 
neurodegenerative disorders such as multiple sclerosis (MS), amyotrophic lateral sclerosis 
(ALS) and Huntington’s disease (HD) 36. After events like stroke or traumatic brain injury, an 
acute inflammation is initiated with microglia and additional cells from the periphery. If the 
inflammation is not resolved, microglia can enter a chronic activation stage releasing high 
amounts of inflammatory mediators, resulting in neuronal death 
47
. When it comes to brain 
tumors, another problem arises when microglia switch to a tumor supporting phenotype. 
Instead of eliminating the tumor cells, microglia have been shown to promote tumor growth 
and invasion of the surrounding tissue 
46
. The following sections focus on brain disorders that 
are covered in the thesis. 
1.2.2 Stroke 
Stroke is one of the leading causes of death today, and many of the survivors suffer from 
permanent disabilities. The incidence of stroke rises exponentially with age. Because of the 
aging populations in the western world, stroke-related disability and increased need of 
healthcare is a growing problem 
48
. There are several common risk factors for stroke that are 
associated with health and life style, e.g. hypertension, diabetes and smoking. Risk factors 
such as atrial fibrillation and transient ischemic attacks (TIA) are less prevalent, but also 
more specific than the general health and life style factors 
48
. 
Stroke is caused by a transient or permanent disturbance in cerebral blood flow, which limits 
the blood supply to a part of the brain. Stroke can be caused by two different mechanisms, 
which are classified as either hemorrhagic or ischemic stroke 
48,
 
49
. 15% of all stroke cases in 
North America and Europe are considered to be due to intracerebral hemorrhage. It is 
commonly caused by hypertensive small-vessel disease, when small aneurysms ruptures and 
causes a bleeding in the brain. It can also be due to intracranial vascular malformations, 
cerebral amyloid antipathy or secondary hemorrhage in a previous infarct 
50
. Ischemic stroke 
is the most common type of stroke, and about 85% of all incidences fall into this category. 
Ischemic stroke is caused by an occlusion of a blood vessel, resulting from thrombosis or 
embolism (e.g. blood clot blockage formed at the site or distal) or global ischemia (e.g. by 
cardiac arrest) 
49,
 
51
. 
The sudden drop in blood flow leads to acute oxygen- and glucose deprivation in the affected 
area, called the ischemic core. The most instant and severe damage of the tissue takes place 
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here in this area, where necrosis can be detected already within a few minutes 
48,
 
49
. The 
surrounding area is called the ischemic penumbra. It has reduced perfusion and some 
functional impairment, but has still structural integrity and can survive longer than the core. 
Within the ischemic area a series of events begins with energy depletion, disturbance in ion 
homeostasis, glutamate release, calcium channel dysfunction, release of free radicals, 
membrane disruption and other changes which triggers necrosis and apoptotic cell death 
48,
 
49
. 
The danger signals released from injured and dying cells triggers the immune system, which 
is rapidly activated and plays an important role in the post-ischemic damage of tissue and 
secondary neurodegeneration 
48,
 
52
. 
Within the first minutes-hours after ischemic stroke (the acute phase), resident microglia cells 
are activated and release pro-inflammatory cytokines, e.g. tumor necrosis factor (TNF) and 
interleukin-1β (IL-1β), nitric oxide (NO) and chemokines, e.g. monocyte chemotactic 
protein-1 (MCP-1/CCL2) and macrophage inhibitory factor 1α (MIP-1α/CCL3) 47, 53. They 
are soon accompanied by infiltrating inflammatory cells from the circulation. In both animal 
models and in tissue from human stroke patients, immune cells such as neutrophils, T-
lymphocytes and monocytes/macrophages are present and contribute to the inflammation 
around the ischemic area 
52,
 
54,
 
55
. In this sub-acute phase (1-5 days after stroke), the infarct is 
spread to the penumbra. Cellular damage is triggered by excitotoxicity, mitochondrial 
disturbances, as well as the production of reactive oxygen species and pro-inflammatory 
cytokines from the immune cells, which are contributing to the tissue injury and secondary 
neurodegeneration 
47,
 
55
. In the late/chronic phase (weeks after stroke), the number of immune 
cells decrease. Beside the pro-inflammatory activity of microglia, they also contribute to 
tissue recovery by scavenging necrotic debris and limiting inflammation by secretion of anti-
inflammatory cytokines, e.g. interleukin-10 (IL-10) and TGF-β 55, 56, 57. 
Current treatment of patients with acute stroke is intravenous tissue plasminogen activator 
(tPA) if the patient arrives to the clinic within 3-4.5 hours after stroke onset or aspirin if 
within 48 hours. The phrase “time is brain” is often used to stress the importance of receiving 
immediate treatment to save the cells at risk in the ischemic penumbra before irreversible 
injury occur. Depending on the cause of the stroke, additional treatments are used, such as 
decompression surgery, antiplatelet agents, endarterectomy or mechanical thrombectomy 
48, 
58
. 
1.2.3 Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common 
form of dementia worldwide. Elderly people are mostly affected (late onset AD), but 4-5% of 
all cases develop the disease before the age of 65 (early onset AD). The aging population is 
also accompanied with increased prevalence of dementia worldwide, a problem that seems 
likely to grow even more in the coming years 
59,
 
60
. AD is clinically manifested by mild and 
gradual memory deficits, which irreversibly advance over time, and decline in cognitive 
function. With the progress of the disease follows manifestations in language disorders, 
visuospatial deficits and executive dysfunctions 
61
. The exact cause of the disease is not well 
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understood, however the most prevalent pathological hallmarks of AD is the extracellular 
accumulation of amyloid-beta (Aβ) aggregates (amyloid plaques) and intracellular aggregates 
of neurofibrillary tangles (tau) together with extensive loss of cortical neurons and synapses 
62. The “amyloid hypothesis” describes Aβ as key factor in triggering the AD 
neurodegenerative cascade, with cerebral accumulations of the amyloid precursor protein 
(APP) cleavage products, the Aβ1-41 and Aβ42 peptides. Formations of Aβ oligomers and 
aggregation into neurofibrillary tangles together with hyperphosphorylated tau disrupts the 
structure and function of the neurons and leads to progressive cognitive decline. Additionally, 
the aggregates trigger a chronic inflammatory response, which also plays a role in the disease 
progression 
63,
 
64
. Several neuroinflammatory mediators are released by both microglia, 
astrocytes and neuronal cells in AD brains 
65
. 
Imaging studies have shown microglia localized around Aβ plaque in the brain of patients 
and in animal models of AD 
66,
 
67
. Microglia are involved in the Aβ clearance by 
phagocytosis and secretion of enzymes involved in Aβ degradation. However, in the late 
stages of AD, the clearance seems very slow and inefficient 
68,
 
69
. Even so, microglia 
activation seems to increase throughout the disease progression 
70
. The Aβ plaques are not 
just toxic to the neurons; together with the signals from the dysfunctional or dying neurons 
they are also activating microglia. Uncontrolled and chronic activation of microglia cells may 
also contribute to neuronal injury. The activated microglia are releasing inflammatory 
mediators, including cytokines, chemokines, NO, free radicals, complement factors and 
prostaglandins which could eventually contribute to additional neural toxicity and cell death 
36,
 
69,
 
71
. 
There is a strong genetic component in AD, with some gene mutations and polymorphisms 
correlated to the disease.  There are several known mutations in genes associated with APP or 
APP processing. The most prevalent mutations are in the APP gene itself , or presenilins 
PSEN1 and PSEN2, which are associated with familial early onset AD 
63,
 
72
. In addition, 
triggering receptor on myeloid cells 2 (TREM2) that is expressed on microglia has also been 
associated with early-onset AD. Most of the AD cases are however sporadic, and several 
potential risk genes are known. The most consistently associated gene is APOE, but several 
phosphokinases like GSK3β and DYRK1A, and the gene encoding Tau are also identified as 
risk genes 
63,
 
73
. Other risk factors for developing AD are age and head injuries, but also 
modifiable life style factors like food intake, physical activity, cognitive reserve, alcohol 
intake and smoking have been found 
63
. 
AD can be difficult to distinguish from other dementias at the clinic, and no definite 
diagnosis can be performed today. The only way to confirm the diagnosis is post mortem 
tissue analysis. Available treatments for AD are mainly focusing on the symptoms, and 
include cognitive training, symptomatic treatment for cognitive decline, as well as usage of 
antidepressants and antipsychotic drugs when needed 
63
. 
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1.2.4 Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with a 
prevalence about 1% at the age of 60, and up to 4% at age 85 
74
. PD is a chronic and slowly 
progressive disorder characterized by clinical manifestations of resting tremor, bradykinesia 
(slowed movements), rigidity and postural instability. The motor symptoms are linked to the 
loss of dopaminergic neurons in substantia nigra (SN) and the subsequent dysfunction of the 
basal ganglia, which are involved in initiation and execution of movements. As the disease 
progresses, other problems like dyskinesia (involuntary movements), pain, impaired 
olfaction, sleep problems, autonomic dysfunctions and neuropsychiatric manifestations 
(dementia, depression and hallucinations) appear 
75
. 
Although most cases of PD are idiopathic, some familial forms of hereditary PD exist with 
several identified susceptibility genes e.g. SNCA (α-synuclein) and PARK2 (parkin) 75. Risk 
factors for PD are advanced age, male gender, European ancestry and exposure to 
environmental toxins. Habits like smoking and coffee consumption on the other hand is 
associated with reduced risk for PD 
74
. 
The degeneration of the dopaminergic neurons in SN is consistent in a neuropathologic 
examination, however different protein pathologies can be detected, like α-synucleinopathy 
or tauopathy. Development of spherical Lewy bodies (LB), which are α-synuclein 
aggregation into insoluble fibrils, and α-synuclein accumulations within neurites (Lewy 
neurites) are common features in PD 
76
.  
Astrogliosis, microgliosis and increased levels of pro-inflammatory mediators in the blood 
and cerebrospinal fluid are often detected in PD patients and PD animal models 
77
. 
Accumulation of α-synuclein is toxic to dopaminergic neurons and also cause activation of 
microglia cells through PRRs.  Additionally, dying and dead neurons also trigger microglia 
activation, leading to sustained activation of microglia and release of inflammatory 
mediators, including TNF, IL-1β, IL-6 and ROS. Chronic activation of microglia and release 
of toxic factors can lead to additional loss of neurons, thereby causing a viscous cycle of 
neuronal degeneration 
78
. Cases with patients who administered the toxin 1-methyl-4phenyl-
1,2,3,6-tetrahydropyrine (MPTP), or animal models based on MPTP or LPS injections, shows 
an acute inflammatory response with microglial activation and release of toxic inflammogens 
followed by the death of dopaminergic neurons. The animal models showed that the 
inflammation preceded cell death, and thereby causative of the neuronal loss 
79,
 
77
. 
Diagnosis of PD cases is mainly based on symptoms, with additional tests for confirmation, 
such as neuroimaging. When the motor symptoms are clinically recognized, about 50-60% of 
the dopaminergic cells in SN are already lost, resulting in 80% depletion in striatal dopamine 
80,
 
75
. The most common treatment for PD is levodopa as replacement therapy to treat the 
motor symptoms. Other treatments can be used, such as dopamine agonists, MAO-B 
inhibitors, COMT inhibitors, surgical intervention and deep-brain stimulation 
81
. 
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1.3 CASPASES 
1.3.1 Caspases 
Caspases, cysteine-aspartic proteases or cysteine-dependent aspartate-specific proteases, are 
a family of proteases (family C14; clan CD) that are part of the signaling pathways 
controlling cell death, inflammation, proliferation and differentiation. As their name implies, 
they carry out their enzymatic properties by recognizing substrates containing aspartate 
(Asp), where they use the cysteine (Cys) residue in their active site to catalyze a peptide bond 
cleavage in the target protein. Even though many proteases use Cys to catalyze peptide-bond 
hydrolysis, the caspase specificity for Asp containing substrates is quite rare for proteases 
82, 
83
. Caspases are expressed in the cells as inactive precursors which are tightly regulated. That 
means they can get rapidly activated upon a specific stimulus to perform a limited 
proteolysis, which in turn activates cascades of events leading to different biological 
responses, depending on the initial stimulus 
82
. 
Caspases are evolutionary conserved from the nematode worms to mammals. The first 
caspase was found in mammalian cells in 1992 as the interleukin-1β-converting enzyme 
(ICE), the inflammatory protease we today call caspase-1 
84,
 
85
. The year after, cloning of the 
cell death gene CED-3 in Caenorhabditis elegans and was shown to have important functions 
in programmed cell death. Since CED-3/ICE-like proteases were structurally similar to 
caspase-1, they proposed that cysteine proteases also could have apoptotic functions in 
mammals 
86
. Soon the field exploded, as more caspases were identified. Gene deletion studies 
and biochemical in vitro experiments were done to characterize them, which especially 
contributed to new developments in the field of cell death. New mechanisms and functions 
for the individual caspases emerged, and they still do 
87
.   
1.3.2 Structure and mechanism of activation 
Caspases are synthesized as inactive single chain polypeptide precursors (zymogens). They 
contain an N-terminal pro-domain followed by a large and a small catalytic subunit, which 
can be divided by a linker peptide (Figure 2). The large peptide is generally composed by ~20 
amino acids, while the smaller subunit is ~10 amino acids 
88
. 
 
 
Figure 2. Overview of general caspase structure, including pro-domain, large- and small catalytic subunit. 
 
The N-terminal domain in the caspases is important for protein binding, and can contain a 
caspase recruitment domain (CARD) or death effector domain (DED). They mediate 
dimerization or binding to larger complexes in the first step of activation. The large subunit 
contains a catalytic dyad of Cys and histidine (His), while the small subunit contains several 
residues that form the substrate binding groove 
82
. 
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The apoptosis related caspases are usually subdivided into initiators and executioners. These 
groups are activated by different mechanisms. The activation of initiator caspases is triggered 
by homodimerization of the caspase monomers and mediated by scaffold proteins. Upon 
apoptotic stimuli, caspases are recruited to activation platforms where adaptor proteins can 
bind to the CARD or DED domains. Homodimerization of caspases leads to auto-proteolytic 
cleavage of the bond between the small and the large subunits, and a subsequent cleavage 
between the pro-domain and the large subunit 
82,
 
89
. 
The effector caspases have shorter pro-domains and exists as inactive pro-caspase dimers. 
They can get activated by cleavage by the initiator caspases, which cleave the bond between 
the large and the small subunits. This allows a conformational change of the complex, 
bringing the two active sites of the dimer together to a mature functional protease. The 
activated executioners can then cleave and activate other executioner caspases, resulting in an 
accelerated activation cascade, and their other physiological substrates 
82,
 
89
. 
1.3.3 Nomenclature and specificity 
To date, up to 14 mammalian caspases have been identified, whereof 12 of them exist in 
human (Figure 3). Caspases are widely spread in the different cell types and tissues, with the 
exception of caspase-14 that is only expressed in keratinocytes 
90
. The human caspases 
includes caspase 1-10, -12 and -14 
87,
 
91
.  
 
Figure 3. Schematic representation of caspase 1-14, grouped according to classification. Number of amino acids 
is indicated to the right. CARD and DED recruitment domains are illustrated in green and orange. Large and 
small catalytic subunits are illustrated in blue. 
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Some caspases are not present in all mammals, for example caspase-11 is a murine enzyme 
that is likely a homologue of the human caspase-4 and -5. The protein that was originally 
named caspase-13 was later found only to be a bovine homologue of caspase-4. Moreover, 
the human caspase-5 is not expressed in mice. Caspase-12 exists both as a full-length and a 
truncated alleles in humans, but only in the full-length form in rodents 
92,
 
93,
 
94
. In evolution, 
there is a tendency towards increased number of caspases over phylogenetic time, ranging 
from four in C. Elegans to seven in Drosophila and 11/12 in mice and human 
95
. 
Caspase substrate specificity is mainly determined by 4 continuous residues on the target 
protein (P4-P3-P2-P1). The P1 position consists of Asp, after which the protein is cleaved on 
the C-terminal side of the sequence 
96
. The preferred residue at P3 is Glu for all the 
mammalian caspases, but other residues can also be used in this position. The P4-P2 residues 
will interact with the caspase catalytic groove, and therefore the specificity for the P4-P2 
positions varies between different caspases. For example caspase-2, -3, -7 are efficient in 
cleaving peptides with the DEVD peptide sequence, but much worse in cleaving a WEHD 
substrate. Conversely, caspase-1, -5 have the opposite affinity to the same target sequences. 
Moreover, caspase-6, -8, -10 prefer (V/I/L)ETD sequences, but caspase-9 prefer LEHD. One 
caspase can however have several more or less efficient target sequences, and several 
caspases can overlap in target specificity 
82,
 
97
. 
1.3.4 Caspase classification 
Classification of caspases is traditionally done according to function, to pro-peptide length 
(related to activation mechanism) or based on synthetic substance preference. The functional 
classification of mammalian caspases is often used, with division into three major functional 
categories; pro-apoptotic caspases, pro-inflammatory caspases and caspases involved in 
keratinocyte differentiation (Fig3). However, the classification has become more complicated 
since new functions for many caspases are constantly discovered, including proliferation, 
differentiation, cell motility and tissue invasion. Also, the same caspase can have functions of 
both apoptotic and anti-apoptotic character 
98
.  
The pro-apoptotic caspases have been discovered for their active role in cell death pathways. 
They are further classified into initiators (including caspase-2, -8, -9, -10) and executioners 
(caspase-3, -6, -7). Initiator caspases activate executioner caspases, which in turn can cleave 
many cellular proteins to trigger apoptosis. However, many non-apoptotic functions have 
been assigned to these caspases as well. The pro-inflammatory caspases are involved in 
maturation of cytokines in innate immune cells. In addition, an inflammatory response to 
infection by programmed cell death (pyroptosis) also exist, which includes caspase-1 
processing of cytokines. Caspase-14 has not been shown to play a significant role in cell 
death or inflammation and form the third class. It is expressed in epidermis and is involved in 
keratinocyte differentiation 
82,
 
88
. 
  21 
1.3.5 Regulation of caspases 
Caspases exist as zymogens in the cells, and their processing and activity needs to be tightly 
regulated. Uncontrolled activation of caspases could have deleterious effects, resulting in 
death of the cell. Several proteins are associated with caspase regulation, and can act by direct 
inhibition or bind to adaptor proteins to hinder the caspase-adaptor protein interaction. The 
first identified endogenous caspase inhibitors were the human inhibitors of apoptosis (IAPs). 
The X-linked IAP (XIAP), and the cellular IAPs, cIAP1 and cIAP2, consist of three 
baculoviral IAP repeats (BIR) domains that mediate protein-protein interactions and a RING 
domain that confers E3 ubiquitin ligase activity. XIAP is a potent inhibitor of caspase 
activity, and acts by direct binding to the caspase. The BIR2 domain inhibits caspase-3 and -
7, whereas BIR3 inhibits caspase-9 activity 
99,
 
100
. cIAP1 and cIAP2 also contain a CARD 
domain, but the mechanism for regulation of caspase activity is not fully understood. The 
cIAPs can bind to the effector caspases, but do not directly inhibit the proteolytic activity. 
IAPs also have other cellular target proteins, and can regulate both apoptotic and 
inflammatory pathways. Other members of the IAP family include NAIP, ML-IAP, ILP2, 
Bruce and Survivin 
100,
 
101
.  
Caspase activation can also be regulated by e.g. the viral inhibitor CrmA and p35/49, or the 
decoy proteins FLIP, COP-1, INCA and ICEBERG, that hinders recruitment to activation 
platforms, or by post translational modifications 
82
. 
1.3.6 Caspase-8 
Caspase-8 can be expressed as 9 different isoforms in human, whereof isoform 1 and 4 are 
the predominant expressed forms in the cells. Isoform 1 consists of 479 amino acids and is 55 
kDa and isoform 4 of 496 amino acids  and is 58 kDa 
102
. The procaspase-8 consists of a long 
N-terminal domain, containing two DED domains, followed by a large and a small catalytic 
subunit (Figure 4). The zymogen is proteolytically processed at Asp
210
, Asp
216
, Asp
374
 and 
Asp
384
 (isoform 1) to generate a tetramer consisting of two small and two large subunits. The 
first cleavage generates the p43/41 intermediate fragments, followed by additional cleavages 
into p26/24, p18 and p10 fragments 
103
. 
 
Figure 4. Caspase-8 structure and processing, with indicated Asp cleavage sites. 
 
Caspase-8 is predominantly known for its function as an apical caspase in apoptotic 
pathways. The extrinsic pathway of apoptosis is triggered by extracellular activation of death 
receptors. They are members of the TNF superfamily, and includes TNFR1, FasR (CD95) 
death receptor 3 (DR3) and TNF-related apoptosis inducing ligand receptor-1/2 (TRAILR). 
Binding of respective ligand to the receptor induce receptor oligomerization and recruits 
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procaspase-8 via the DED to the death inducing signaling complex (DISC) formed at the 
intracellular part of the receptor. The DISC complex also includes adaptor proteins, such as 
FADD, TRADD, TRAF or RIP. Dimerization and activation of caspase-8 can initiate 
apoptosis by direct cleavage of executioner caspases or through the intrinsic apoptotic 
pathways by e.g. cleavage of Bid. Bid and other proteins facilitate cytochrome c release from 
the mitochondria into the cytoplasm. Cytochrome c interacts with APAF1, ATP and caspase-
9 to form the apoptosome, resulting in caspase-9 activation and subsequent activation of 
executioner caspases 
104
. Depending on the strength and duration of the stimuli, the type of 
death receptor and adaptor proteins, the activation can also initiate other cellular processes. 
Apart from the role in apoptosis, caspase-8 can also promote cell differentiation, regulate cell 
proliferation, regulate autophagy, promote cellular migration and immune signaling 
105,
 
106,
 
107
. Caspase-8 has also been shown to regulate necroptosis (a regulated form of necrosis) by 
suppressing RIP1/RIP3. Inhibition of caspase-8 in inflammatory activated microglia can 
induce necroptosis, however not in neurons, astrocytes or unactivated microglia 
108,
 
109
. 
1.3.7 Caspase-3 
Human caspase-3 is expressed as a 277 amino acids long propeptide of 32 kDa 
110
. It consists 
of a short N-terminal domain, followed by a large and a small catalytic subunit, which are 
processed at Asp
28
, Asp
175
 and Asp
180
 (Figure 5).  The zymogen is first cleaved into two 
heterodimer complexes consisting of the p19/p12 subunits, followed by autocatalytic 
cleavage of the p19 resulting in the p17/12 tetramer 
111
.  
 
Figure 5. Caspase-3 structure and processing, with indicated Asp cleavage sites. 
 
The traditional view of caspase-3 is as executioner of apoptosis. For example caspase-8 
mediated cleavage of caspase-3 in the extrinsic apoptotic pathway, or caspase-9 mediated 
cleavage in intrinsic apoptotic pathway results in activation of caspase-3. Activated caspase-3 
can then cleave specific cellular substrates which results in demise of the cell 
104
.  Poly (ADP-
ribose) polymerase (PARP) is a well-known substrate for caspase-3. Cleavage of PARP 
facilitates cellular disassembly and can be used as a marker to detect apoptosis 
112
.  
Caspase-3 is also involved in several non-apoptotic processes. For example, low levels of 
active caspase-3 are needed for some of the synaptic changes that underlie memory in 
neuronal cells 
113
. Caspase-3 is involved in neuronal differentiation, migration and 
maintenance of stem cell quiescence 
114
. Amyloid precursor protein can be cleaved by 
caspase-3, which generates a small fragment called C31. Caspase-3 is also important for the 
differentiation of many other cell types and is involved in inflammatory signaling 
107
. 
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1.3.8 Caspase signaling in microglia and inflammation 
Caspase-1 is well known for its role in inflammation. Activation of NLRs leads to 
inflammasome formation, and includes maturation of caspase-1. The activated caspase-1 
mediates processing and maturation of IL-1β and IL-18, which are released during 
inflammation 
115
. 
Apart from their traditional roles in apoptosis, caspase-3 and -8 have been associated with 
inflammatory signaling. Lately, caspase-8 has been shown to be involved in inflammasome 
modulation and also in direct IL-1β regulation 115. Moreover, caspase-8 is required for T and 
B cell clonal expansion and for lymphocyte homeostasis and immune function. Caspase-3 has 
also been linked to lymphocyte activation and B cell differentiation 
116,
 
107
. 
Interestingly, caspases have been associated with macrophage differentiation. Caspase-3, -8 
and -9 were shown to contribute to the differentiation of monocytes to macrophages. 
Caspase-8 has also been linked to prevention of sustained activation of nuclear factor kappa 
B (NFkB) during differentiation and maintenance of macrophage activation 
117,
 
118
. 
Several studies in this thesis have been inspired by our earlier finding of caspases controlling 
the activation of microglia cells 
119
. Microglia stimulated with various inflammogens showed 
activation of caspase-8 and caspase-3/7, in the absence of cell death both in vivo and in vitro. 
The orderly activation of caspase-8 and caspase-3/7 lead to activation of NFκB pathways 
through the processing and activation of protein kinase-Cδ (PKCδ), and result in transcription 
of pro-inflammatory cytokines (Figure 6). Inhibition or knockdown of the caspases hindered 
microglia activation and release of the inflammatory mediators. Moreover, these caspases 
could also be put in the context of neurodegenerative disorders, where detection of caspase-8 
and -3 were found in activated microglia in patients with AD and PD 
119
.  
 
Figure 6. Pro-inflammatory activation of microglia leads to caspase-8 and -3/7 cleavage and activation of NFκB 
pathways. 
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2 AIMS OF THE THESIS 
 
The overall aim of the thesis was to investigate the roles of active caspase-8 and caspase-3 in 
microglia (mainly), beyond their function in apoptosis. 
 
Paper I: In the first paper we were interested in understanding how activation of caspase-3 in 
some situations can lead to activation of microglia cells, while in other circumstances can 
lead to cell death. 
 
Paper II: Using a conditional knock-out of the CASP8 gene in microglia cells, we wanted to 
investigate the effect on microglia activation and the possible beneficial effect on neuronal 
survival in mouse models of Parkinson’s disease. 
 
Paper III: The expression of cleaved caspase-8 and -3 in activated microglia cells were 
investigated in post mortem tissue from stroke patients and in a mouse model of stroke to find 
the temporal and spatial activation patterns. 
 
Paper IV: In a screening for proteases related to processing of amyloid precursor protein we 
found mutations in CASP8 in patients with late onset Alzheimer’s disease. We are here 
investigating if the mutated forms of caspase-8 have functional differences from the wildtype 
caspase-8 in vitro.  
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3 RESULTS 
3.1 PAPER I. 
Regulation of caspase-3 processing by cIAP2 controls the switch between pro-
inflammatory activation and cell death in microglia. 
A previous finding of the group showed a novel role for caspases in the microglia activation 
process. Caspase-8 and -3 activation were shown to regulate microglia pro-inflammatory 
activation, in the absence of cell death 
119
. But this discovery also raised many questions; how 
can these caspases, which are commonly known for their role in apoptosis, become activated 
without killing the cells? What is preventing them from their apoptotic functions? 
To answer these questions, we used the BV2 microglia cell line to compare the activation and 
cell death pathways. Upon treatment with lipopolysaccharide (LPS) to induce pro-
inflammatory activation or staurosporine (STS) to induce cell death, we found a difference in 
the cleavage pattern of caspase-3. Caspase-3 is processed in two steps; the first cleavage 
generates the p19/p12 complexes, which are thereafter further processed into p17/p12 
complexes. After activating the cells we could only detect the first step of caspase-3 
processing into the p19 form (p19/p12 complex), but with the cell death stimuli we could also 
detect the fully processed form, p17 (p17/p12 complex). Interestingly, p17 was also detected 
in the nuclei upon cell death stimuli, while p19 was retained in the cytoplasm in both 
conditions. 
But what is hindering the processing from the p19 to p17 form in the activated microglia? We 
started by investigating if any of the caspase inhibitors of the IAP family were involved. 
After microglia activation we found an increase in cIAP2 both on mRNA and protein levels 
in the cells, but not of XIAP or cIAP1. Could it be that cIAP2 is hindering the full processing 
of caspase-3 in activated cells? Indeed, using proximity ligation assay we could detect an 
increase in interactions between cIAP2 and cleaved caspase-3 upon microglia activation. 
Using subcellular localization assay we could also confirm the presence of cIAP2 in the 
cytoplasm, where we have previously detected the p19 form of caspase-3. 
To confirm that cIAP2 is hindering the p19 to p17 conversion and retain p19 in the 
cytoplasm, we knocked down cIAP2. Indeed, knockdown of cIAP2 in the activated cells lead 
to an increased p19 to p17 conversion and caspase-3 activity. The localization of active 
caspase-3 can regulate the ability to process cytoplasmic substrates, like PKCδ during 
microglia activation, or nuclear, like PARP under cell death conditions. After cIAP2 
knockdown or STS treatment we did indeed find PARP cleavage, indicating that cIAP2 is 
hindering the caspase-3 to induce cell death during microglia activation. Interestingly, LPS 
treatment after knockdown of cIAP2 did not just induce cell death, but also hindered 
microglia activation. 
Finally, using the compound BV6 to reduce the cIAP2 and caspase-3 interaction we 
confirmed the results obtained with cIAP2 knock down. BV6 was able to suppress the 
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inhibitory effect cIAP2 has on the full processing of caspase-3, leading to reduced microglia 
activation and increased cell death. 
In summary, cIAP2 regulation of caspase-3 can be seen as a switch between pro-
inflammatory activation and apoptosis in microglia cells. cIAP2 hinders further processing of 
p19 to p17 in activated microglia, and entry to the nucleus. The cytoplasmic localization of 
caspase-3 promotes the pro-inflammatory activation and hinders apoptosis. 
 
 
Figure 7. cIAP2 regulation of caspase-3 processing controls the switch between pro-inflammatory and cell death 
pathways. 
 
3.2 PAPER II 
Deletion of caspase-8 in mouse myeloid cells blocks microglia pro-inflammatory 
activation and confers protection in MPTP neurodegeneration model. 
The finding of caspases controlling microglia activation 
119
 encouraged us to provide the 
genetic evidence in a caspase-8 knockout mice model. Since sustained microglial pro-
inflammatory activation is associated with the pathogenesis in neurodegenerative disorders, 
we decided to examine our genetic model in the context of neurodegeneration using a mouse 
model for Parkinson’s disease (PD). The 1-methyl-4phenyl-1,2,3,6-tetrahydropyrine (MPTP) 
model has a significant inflammatory response and degeneration of dopaminergic neurons. In 
addition we used an acute LPS model, which also includes a strong inflammatory response 
and neurotoxicity in the substantia nigra. 
The conditional knockout model of caspase-8 in myeloid cells was created by crossing mice 
bearing a floxed allele of CASP8 and a transgenic line expressing Cre under the control of the 
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Lysozyme 2 gene (Cre
LysM
Casp8
fl/fl
).  After intranigral injections of LPS or administration of 
MPTP, a significant decrease of cleaved caspase-8 is observed in Iba1 positive cells in the 
Cre
LysM
Casp8
fl/fl
 mice as compared to the Casp8
fl/fl 
mice used as control, confirming the 
depletion of caspase-8 in the myeloid brain cells. Isolation of microglia cells from LPS 
injected and intact mice showed a low level of caspase-8 gene deletion in resident microglia, 
but a very high rate of caspase-8 gene deletion in the activated cells from the LPS mice. 
Immunohistochemical analysis after intranigral injections of LPS showed equal numbers of 
Iba1-positive cells and marked changes in microglia morphology, indicating activation, in 
both the Casp8
fl/fl 
and Cre
LysM
Casp8
fl/fl
 mice. Interestingly, there is also a clear 
downregulation of the pro-inflammatory marker CD16/32 detected in the caspase-8 deficient 
mice, indicating caspase-8 deletion hinders microglia activation in the LPS model. 
Additionally, the cleaved caspase-8 found in the Casp8
fl/fl 
mice was mostly restricted to 
CD16/32 labeled microglia. qPCR analysis of inflammatory mediators confirmed the 
upregulation of pro-inflammatory markers in the Casp8
fl/fl 
mice, but revealed significant 
prevention of the same markers in the Cre
LysM
Casp8
fl/fl
 mice. 
The results were then confirmed in the MPTP model of PD. We could detect similar numbers 
of microglia in the mesencephalon and striatum, but a significantly higher density of pro-
inflammatory activated microglia in the Casp8
fl/fl 
mice as compared to the Cre
LysM
Casp8
fl/fl
 
mice. The caspase-8 activation in microglia was also detected mainly in the CD16/32 and 
Iba1 positive cells in the Casp8
fl/fl 
mice, but rarely in the Cre
LysM
Casp8
fl/fl
 mice. 
A quantification of the dopaminergic nigral neurons revealed a large reduction in Tyrosine 
hydroxylase (TH) positive neurons upon MPTP administration in the Casp8
fl/fl 
mice, but a 
smaller, close to significant, decrease in the Cre
LysM
Casp8
fl/fl
 mice. However, analysis of the 
striatal dopaminergic nerve terminal density showed significant higher loss in the Casp8
fl/fl 
mice than the Cre
LysM
Casp8
fl/fl
 mice in comparisons to the controls. 
We could hereby conclude that caspase-8 gene deletion (Cre
LysM
Casp8
fl/fl
) in myeloid cells 
demonstrated a high efficiency in activated but not in resident microglia. The caspase-8 
deletion led to reduced pro-inflammatory activation of microglia upon LPS or MPTP 
treatment and was accompanied by a protective effect on the nigro-striatal dopaminergic 
system in the MPTP model. 
 
3.3 PAPER III 
Temporal investigation of caspase-8 activation in myeloid cells in human stroke 
subjects. 
Based upon the earlier finding of caspase-8 and -3/7 regulating microglia activation 
119
, we 
decided to investigate this caspase activation in microglia cells in stroke. Here we had the 
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opportunity to study their activation pattern in post mortem tissue from patients who had 
suffered an ischemic stroke. 
Ischemic stroke is caused by a blockage or reduction in cerebral blood flow and leads to 
tissue damage and recruitment and activation of immune cells, including resident microglia 
and infiltrating macrophages. The ischemic core suffers the instant damage, which gradually 
spread to the surrounding penumbra unless the blood flow is rapidly restored and the 
inflammation is resolved 
120
. 
We started with immunohistochemical and immunofluorescent stainings of tissue from 
human stroke subjects. Antibodies detecting cleaved caspase-8 or -3 were used together with 
CD68, which detects activated microglia/macrophages (MMs). We could detect large 
numbers of CD68-positive MMs in the penumbra and ischemic core, and confirm the 
presence of active caspase-8 and -3 in the MMs. 
Next, we wanted to understand the temporal and spatial expression of caspases after stroke. 
We investigated this aspect in a permanent middle cerebral artery occlusion (pMCAO) mouse 
model, where brain tissue was analyzed 6, 24 and 48 hours post occlusion. Already after 6 
hours, morphological changes could be detected in Iba1-positive MMs in the penumbra. 
Morphological changes associated with MM activation were increasing at the 24 and 48 
hours’ time points. Here we choose to focus on the apical caspase-8. It could be detected at 
very low levels in Iba1-positive cells already at 6 hours, and showed an increased expression 
at the later time points. Interestingly, increasing levels of active caspase-8 correlated with the 
morphologically changes associated with activated MMs. Increased caspase levels and 
activation both became more prominent in the penumbra the closer the cells were to the 
ischemic core. 
Finally, we were able to stain tissue from stroke patients who had suffered from two stroke 
events, one recent and one older. We discovered that expression of active caspase-8 and -3 
could only be detected in the CD68 positive cells of the recent stroke area, but not in the 
older. Analysis of a panel of stroke patients with different ages of the stroke areas (n=9) and 
controls (n=5) suggested a correlation between presence of active caspases in CD68-positive 
cells and the age of the stroke area. The caspase expression decreased over time, along with 
decreasing numbers of CD68-positive cells. 
The distinct pattern of active caspase-8 observed around the infarct area suggests that 
immunohistochemical stainings of cleaved caspase-8 could be used as an additional 
diagnostic marker for ischemic stroke. 
In summary, our data illustrates a temporal and spatial activation of caspase-8 and -3 in 
microglia/macrophages after ischemic stroke. The caspase expression correlates with the time 
after stroke in analysis of the patient tissue and with the proximity of the infarct core, as 
shown in the pMCAO animal stroke model. 
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3.4 PAPER IV 
Association with Alzheimer’s disease and functional analysis of rare CASP8 variants. 
In this paper we wanted to screen for mutations in genes involved in amyloid precursor 
protein (APP) metabolism, including caspase-8 and -3, in patients with late-onset AD to 
identify novel genes associated with the etiology of AD. 
Dominant mutations in genes encoding APP and presenilin 1 and 2 are common causes of 
familial early-onset AD, and has recently been recognized as rare variants in late-onset AD as 
well 
63,
 
72,
 
121
. The dysregulation of APP processing and accumulation of amyloid-beta (Aβ) 
are described as central events in the development of AD according to the amyloid cascade 
hypothesis 
63,
 
64
. We were therefore interested in screening for other genes involved in APP 
metabolism, and included nine candidates in our study. We performed a rare variant 
association study using targeted sequencing in 1886 AD cases and 1700 controls. We also 
included APP, PSEN1, PSEN2 and TREM2 to identify known casual genes in our cohort to 
evaluate our study. 
The variant-burden test reached nominally significant association for PSEN1, TREM2, 
APH1B and CASP8. PSEN1 showed strong association with 23/1883 rare variants in cases 
and 6/1700 in controls (burden test p=0.0027). For TREM2, rare variants were observed in 
114 cases and 52 in controls (burden test p=1.2x10
-5
). For the candidate genes involved in 
APP metabolism, the APH1B rare variants was found in 17 cases and 6 controls (p=0.031), 
but was not found to be significant when corrected for multiple testing. CASP8 however 
showed a significant association with AD in burden analysis after corrections for multiple 
tests. We observed rare variants in 26 cases and 4 controls (p=8.6x10
-5
, OR=5.93), which 
were all confirmed with capillary sequencing. 
For CASP8 we found two protein coding variants that were overrepresented in AD cases, 
here called CASP8mut1 and CASP8 mut2. Structural analysis of the two variants shows that the 
substitutions affect exposed amino acid residues in death domain 2 within the prodomain and 
the large catalytic subunit of caspase-8 respectively.  
We were then interested to see if the substitutions had an effect on caspase-8 function. 
Plasmids encoding for the two variants were transfected into caspase-8 defective 
neuroblastoma cells and evaluated in functional studies. The CASP8mut1 variant showed 
higher accumulations of active caspase-8 in aggregate structures in immunofluorescence 
analysis and higher levels of caspase-8 and its proteolytic fragments with immunoblotting, as 
compared to CASP8 wildtype. For the CASP8 mut2 variant reduced levels of caspase-8 and 
processed fragments were shown. In addition, the CASP8 mut2 variant showed a significant 
reduction in caspase-8 activity (LETDase activity), while CASP8mut1 did not appear to affect 
its enzymatic activity. However reduced activation (DEVDase activity) of caspase-3, a 
substrate and downstream effector of caspase-8, was observed for both CASP8 variants. 
Moreover, both CASP8 variants are able to process APP and generate the caspase cleaved 
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APPΔC31 fragment, as judged by immunoblot analysis. However, if they are as efficient as 
CASP8 wildtype remains unclear. 
To summarize: In this study we used targeted sequencing and variant-burden test and thus 
identified a strong association of rare missense variants in the CASP8 gene with AD. 
Functional studies of two CASP8 variants showed altered expression of the caspase-8 protein 
and effect on caspase-8 and caspase-3 activity. The reduced enzymatic activity may have 
effect on several cellular processes that are regulated through caspase activity and contribute 
to brain homeostasis, which justifies further studies of caspase-8 role in the etiology of late-
onset AD. 
 
  
 
Figure 8. Screening of a large cohort of AD patients and controls by targeted sequencing identified a strong 
association of rare missense variants in the CASP8 gene with AD. Mutations in CASP8 gene are indicated by 
red arrows.
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4 DISCUSSION 
The studies in this thesis have focused on the roles of caspase-8 and -3 in microglia activation 
and in disease. Several projects were based on a previous finding in the group of novel roles 
for caspases in microglia activation. Upon pro-inflammatory stimulus, activation of caspase-8 
and -3 were shown to regulate microglia activation, in the absence of cell death. This 
discovery raised many new questions: These caspases are well known for their role in 
apoptosis, but here they are not killing the cells. What is preventing them from their apoptotic 
functions? Can we present genetic evidence of caspase involvement in microglia activation? 
Can we detect these caspases in activated microglia in disease? 
In order to answer these questions we started by focusing on the apical caspase-8. In Paper II 
we wanted to provide genetic evidence for the caspase regulation of microglia activation. We 
created a conditional knock-out of caspase-8 in microglia cells using the Cre-Lox system in 
mice. Knock-out of caspase-8 reduced the microglia pro-inflammatory phenotype and 
showed a reduction in neuronal cell death in a Parkinson´s disease model. It is interesting to 
speculate that targeting these caspases could be used as a strategy to reduce microglia pro-
inflammatory activation and neurotoxicity in disease. 
In Paper I we wanted to understand why the caspases are not killing the cells during 
microglia activation. Here we describe a mechanism for how cIAP2 can act as a molecular 
switch between pro-inflammatory- and cell death pathways in microglia by regulating the 
processing of caspase-3. In this paper we also use a SMAC mimetic, the BV6 compound, to 
reduce cIAP2 inhibition of caspase-3 processing. Through this mechanism, treatment of 
microglia with the BV6 compound resulted in reduced microglia activation. However, if 
reducing the number of pro-inflammatory activated microglia by induction of cell death is 
beneficial in disease remains to be investigated. Caspase inhibitors such as e.g. Q-VD-OPh 
might be a more direct approach for therapeutic purposes. Still, the effect on other signaling 
pathways and other cell types in the brain has to be taken into account as well. 
Another important question to be asked is in which phase of the disease it is beneficial to 
target caspases in microglia activation? In Paper III we investigated the temporal and spatial 
expression of caspase-8 and caspase-3 in activated microglia after stroke. We examined the 
caspase expression in a panel of stroke patients, and concluded that detection of caspases 
correlated with the age of the ischemic area. If considering using caspases as a way to target 
microglia activation, one has to consider this time-window for interventions. 
In Paper IV we identified two rare variants of CASP8 associated with late-onset Alzheimer’s 
disease. We also showed in vitro that these mutations could lead to a reduction in enzymatic 
activity in a neuroblastoma cell line. Although a moderate change, reduced activity over a 
lifetime (as in late-onset AD) could have consequences that are accumulating over time. 
Considering the roles of caspase-8 and its downstream effector caspase-3 in several cellular 
processes, the altered enzymatic activity can affect the different cell types in many ways. 
Here we have studied the effect of overexpression of the mutated caspases after 24 hours. In 
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the future it would be very interesting to use knock-in CASP8 mutations in cell lines or in an 
in vivo model and study their long-term effect. It would also be interesting to study the 
CASP8 mutations in microglia cells to investigate their effect on microglia activation. 
In summary; in this thesis we studied the role of caspase-8 and -3 in microglia activation and 
disease. We provided genetic evidence for caspase-8 regulation of microglia pro-
inflammatory activation (Paper II) and described a mechanism for how caspase-3 is 
prevented of killing the cells during activation (Paper I). We also described the expression 
pattern of those caspases in microglia cells after stroke (Paper III), and provided evidence of 
rare mutations in caspase-8 associated with late-onset Alzheimer´s disease (Paper IV). 
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